<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Manganese-based macrocyclic chelates as novel MRI contrast agents: In vivo imaging in a porcine model - Health AI Hub</title>
    <meta name="description" content="This study investigates novel manganese-based macrocyclic chelates (MBCAs) as potential alternatives to gadolinium-based MRI contrast agents (GBCAs) due to safe">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Manganese-based macrocyclic chelates as novel MRI contrast agents: In vivo imaging in a porcine model</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20358v1" target="_blank">2511.20358v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> P√•l B. Marthinsen, Tuva R. Hope, Wibeke Nordh√∏y, Deirdre B. Cassidy, Adrian P. L. Smith, Paul M. Evans, Atle Bj√∏rnerud
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> physics.med-ph
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20358v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20358v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This study investigates novel manganese-based macrocyclic chelates (MBCAs) as potential alternatives to gadolinium-based MRI contrast agents (GBCAs) due to safety concerns. Researchers evaluated the distribution, kinetics, and T1-enhancing properties of three MBCAs in a porcine model, finding several candidates with comparable vascular T1 relaxation efficacy to a reference GBCA and predominantly renal clearance, suggesting their potential for safer contrast-enhanced MRI procedures.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is critically important for medical imaging, aiming to replace gadolinium-based contrast agents, which are associated with retention concerns, with safer manganese-based alternatives that leverage an endogenous metal with established biochemical excretion pathways, potentially improving patient safety and expanding MRI accessibility.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>N/A - The abstract does not mention any application of AI in this research.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Three novel Mn-based macrocyclic chelates (AH114608, GEH300017, GEH200486) were tested in a porcine model and compared against gadoterate meglumine (a GBCA).</li>
                    
                    <li>All four contrast agents demonstrated T1-enhancing properties in the blood pool; GEH200486 had the largest increase in T1 relaxation rate (R1), GEH300017 was comparable to gadoterate meglumine, and AH114608 showed a lower peak R1 change.</li>
                    
                    <li>AH114608 exhibited a persistent R1 increase in the liver, kidney, and myocardium, while GEH300017 and GEH200486 showed a lesser but persistent liver enhancement compared to gadoterate meglumine.</li>
                    
                    <li>All tested CAs displayed similar bi-exponential plasma kinetics, characterized by a rapid distribution phase followed by a slower elimination phase.</li>
                    
                    <li>The study identified MBCA candidates that primarily undergo renal clearance, similar to desired characteristics for contrast agents.</li>
                    
                    <li>These novel MBCAs demonstrated comparable efficacy to the reference GBCA in terms of vascular T1 relaxation, suggesting their potential for clinical utility.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>Twelve adult female pigs were divided into four groups (n=3 per CA) to evaluate three novel Mn-based macrocyclic chelates (AH114608, GEH300017, GEH200486) against gadoterate meglumine. In vivo imaging was performed using 3 T MRI, with longitudinal T1 relaxometry analysis conducted in multiple organs at five timepoints 30 minutes apart. Contrast agent kinetics were assessed by analyzing plasma CA concentrations using Inductively Coupled Plasma ‚Äì Optical Emission Spectrometry (ICP-OES).</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>All tested contrast agents effectively enhanced T1 relaxation in the blood pool, with GEH200486 showing the strongest effect, while GEH300017 exhibited comparable efficacy to gadoterate meglumine. AH114608 caused a persistent R1 increase in the liver, kidney, and myocardium. GEH300017 and GEH200486 also demonstrated persistent, albeit lesser, liver enhancement compared to the GBCA. All agents shared similar bi-exponential plasma kinetics. Crucially, the study identified MBCA candidates with predominantly renal clearance and vascular T1 relaxation efficacy comparable to the reference GBCA.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The identification of manganese-based macrocyclic chelates with comparable T1-enhancing properties and a favorable renal clearance profile holds significant clinical impact. These agents could provide a safer alternative to gadolinium-based contrast agents, mitigating concerns regarding gadolinium retention, and thus potentially broadening the safe use of contrast-enhanced MRI for a wider patient population, including those with compromised renal function or who require frequent examinations.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly mentioned in the abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The study concludes that these novel Mn macrocyclic CAs can be utilized with routine clinical protocols and could potentially serve as an alternative to GBCAs. This implies a need for further preclinical validation, comprehensive toxicology studies, and ultimately, human clinical trials to confirm their safety, efficacy, and suitability for various clinical applications in humans.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Radiology</span>
                    
                    <span class="tag">Diagnostic Imaging</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Nephrology</span>
                    
                    <span class="tag">Cardiology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Manganese-based contrast agents</span>
                    
                    <span class="tag tag-keyword">MRI</span>
                    
                    <span class="tag tag-keyword">Contrast media</span>
                    
                    <span class="tag tag-keyword">Gadolinium alternatives</span>
                    
                    <span class="tag tag-keyword">Pharmacokinetics</span>
                    
                    <span class="tag tag-keyword">T1 relaxometry</span>
                    
                    <span class="tag tag-keyword">Porcine model</span>
                    
                    <span class="tag tag-keyword">Renal clearance</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Objectives: Mn-based MRI contrast agents (MBCAs) have recently been proposed as alternatives to the currently used class of Gd-chelates. Unlike Gd, Mn is an endogenous paramagnetic metal with known biochemical pathways in the human body for excretion and metal regulation, which may alleviate the raised concerns about the safety of existing GBCAs. The aim of this study was to investigate the distribution, kinetics and image enhancement properties of a class of novel Mn-based macrocyclic chelates in a porcine model. Methods: Macrocyclic MBCAs, AH114608, GEH300017 and GEH200486, were tested and compared to gadoterate meglumine. Twelve female adult pigs were divided into four groups (n=3 for each CA). At 3 T MRI, T1 relaxometry analysis were measured longitudinally in multiple organs at five timepoints 30 minutes apart. CA kinetics was estimated from analysis of plasma CA concentrations by ICP-OES. Results: All four CAs exhibited T1-enhancing properties in the blood pool with GEH200486 having the largest increase in T1 relaxation rate (R1), GEH300017 and gadoterate meglumine having similar R1 increase and AH114608 a lower peak R1 change. A persistent increase in liver, kidney and myocardium R1 was observed with AH114608. To a lesser extent, a persistent increase of liver enhancement was also observed in T1-weighted images for GEH300017 and GEH200486 compared to gadoterate meglumine. All four CAs had similar bi-exponential plasma kinetics characterized by a rapid distribution phase and a slower elimination phase. Discussion: We have identified MBCA candidates with predominantly renal clearance and comparable efficacy in terms of vascular T1 relaxation, and comparable to the reference GBCA. The T1-enhancing properties of these novel Mn macrocyclic CAs can be used with routine clinical protocols and could be potentially utilised as an alternative to GBCAs for contrast-enhanced MRI procedures.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>15 pages, 8 figures and 3 tables</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>